Heightened IDO1 levels predict Bacillus Calmette-Guerin failure in high-risk non-muscle-invasive bladder cancer patients.

ABSTRACT: Recent studies have indicated a potential link between immune-related gene expression and Bacillus Calmette-Guèrin (BCG) treatment response in non-muscle-invasive bladder cancer (NMIBC) patients, however, prognostic gene signatures have not significantly improved risk stratification beyond clinical characteristics. To identify predictive biomarkers in T1 high-risk (HR) bladder cancer (BC) patients responding to BCG treatment, a gene signature was derived from a discovery cohort of 73 BCG-naïve patients, both responders and non-responders, using the publicly available dataset GSE1542618. Among the identified genes, Indoleamine 2,3-dioxygenase (IDO1), an immunosuppressive enzyme, emerged as a crucial determinant of treatment outcomes. The association between IDO1 expression and worse prognos

SUBMITTER: Turdo A 

PROVIDER: S-EPMC12033280 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature